Last reviewed · How we verify
Dimolegin
Dimolegin is a Small molecule drug developed by Avexima Diol LLC. It is currently in Phase 3 development. Also known as: DD217.
Dimolegin is a medication being studied in clinical trials for the prevention of Venous Thromboembolism (VTE) and treatment of COVID-19, among other conditions. It is being compared to sodium enoxaparin in a randomized, double-blind, double-masked trial for patients undergoing total hip or knee replacement.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Dimolegin |
|---|---|
| Also known as | DD217 |
| Sponsor | Avexima Diol LLC |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Dimolegin® (60 mg) for Patients With Moderate COVID-19: A Non-Interventional Study
- Dimolegin® (60 mg) Given Once Daily in Patients Undergoing Total Hip or Knee Replacement Compared to Enoxaparin (PHASE3)
- A Study to Evaluate Dimolegin in Prevention of Thromboembolic Complications During Knee Replacement (PHASE2)
- Clinical Trial of Dimolegin (DD217) in Prevention of Thrombotic Complications in Patients With COVID-19 (PHASE3)
- A Study of Pharmacokinetics, Safety and Tolerability of Dimolegin (DD217) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dimolegin CI brief — competitive landscape report
- Dimolegin updates RSS · CI watch RSS
- Avexima Diol LLC portfolio CI
Frequently asked questions about Dimolegin
What is Dimolegin?
Who makes Dimolegin?
Is Dimolegin also known as anything else?
What development phase is Dimolegin in?
Related
- Manufacturer: Avexima Diol LLC — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: DD217
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing